Recruiting
Phase 2

Efgartigimod PH20

Sponsor:

argenx

Code:

NCT07760818

Conditions

Sjogrens Disease

Primary Sjögren's Syndrome Painful Sensory Neuropathies

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

efgartigimod PH20 SC

Placebo PH20 SC

Study Details

Brief summary:

This study aims to assess the efficacy and safety of efgartigimod PH20 in adults with Sjogren's Disease (SjD) associated with nerve damage. The study will assess how efgartigimod PH20 affects symptoms of SjD specifically linked to the peripheral nervous system; the safety and tolerability of efgartigimod PH20; and whether receiving efgartigimod PH20 affects the participant's quality of life.

Conditions

Sjogrens Disease

Primary Sjögren's Syndrome Painful Sensory Neuropathies

Study ID

NCT07760818

Start date

Oct 9, 2026

Status verified date

Nov, 2026

Completion date

Jul 28, 2029

Anticipated

Primary completion date

Jul 28, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF
  • Meets the following SjD criteria: Fulfilled American College of Rheumatology and the European Alliance of Associations for Rheumatology classification 2016 SjD criteria before screening; Moderate-to-severe disease defined as a ESSDAI ≥ 5 or clinESSDAI ≥ 6 with PNS domain score of ≥ 5 (ie, a score of at least low activity) at screening; Anti-Ro/SS-A positive at a central laboratory at screening
  • Meets the following SjD-associated polyneuropathy criteria: Diagnosis of SjD-associated SMPN, SPN or sensory ganglionopathy, with neuropathy duration ≤ 5 years at screening and signs of active neuropathic disease development within the last 12 months; patients with co-existing SjD-associated small fiber neuropathy are eligible; No alternative diagnosis of neuropathy etiology; Total mTCNS ≥ 6 at screening; mTCNS sensory test score <level 3 at screening (does not apply to sensory ganglionopathy cohort where any severity is acceptable)

Exclusion Criteria:

  • Besides the indication under study, known medical conditions that would interfere with an accurate assessment of clinical symptoms of SjD-associated SMPN or SPN or gangliopathy, confound the study results, or puts the participant at undue risk.
  • Associated (also known as secondary) SjD, defined as overlap with another autoimmune rheumatic or systemic inflammatory condition (eg, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, or idiopathic inflammatory myopathy).
  • Active fibromyalgia which is not adequately controlled in the judgment of the investigator, or participant is receiving fibromyalgia treatment that has not been stable treatment for at least 12 weeks before screening.
  • An alternative etiology for SMPN/SPN/sensory ganglionopathy or insufficient evidence of the diagnosis.
  • Any severe SjD manifestation or other health condition not adequately controlled at screening or baseline that may put the participant at undue risk based on the investigator's opinion.
  • Comorbidities (eg, asthma, chronic obstructive pulmonary disease) which have required 3 or more courses of systemic (oral, IV, or IM) glucocorticoids within the previous 12 months.
  • History of malignancy unless considered cured by adequate treatment with no evidence of recurrence for ≥ 3 years; before first IMP administration.

Study Design

Enrollment

75 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Double-blinded treatment period (DBTP): Efgartigimod PH20 SC

Participants receiving efgartigimod PH20 SC during the double-blinded treatment period

placebo comparator: Double-blinded treatment period (DBTP): Placebo PH20 SC

Participants receiving placebo PH20 SC during the double-blinded treatment period

experimental: Open-label treatment period (OLTP)

Participants receiving efgartigimod PH20 SC during the open-label treatment period

Interventions

efgartigimod PH20 SC

subcutaneous efgartigimod PH20 SC given by prefilled syringe

Placebo PH20 SC

subcutaneous placebo PH20 SC given by prefilled syringe

Primary outcome measure

  • Change from baseline in modified Toronto Clinical Neuropathy Score (mTCNS) total score at the end of Part A [ Time Frame: Up to 48 weeks ]

Central Contacts and Locations

Locations

Sarasota Arthritis Research Center

Recruiting

Sarasota, Florida, United States, 34239

Contacts

Principal Investigator:

Jaishree Manohar, Dr.

Vantage Clinical Trials Tampa

Recruiting

Tampa, Florida, United States, 33614

Contacts

Principal Investigator:

Edgard Janer, Dr.

Revive Research Institute Inc

Recruiting

Sterling Heights, Michigan, United States, 48313

Contacts

Principal Investigator:

Syed Husain, Dr.

More Information

Sponsor

argenx

Last update posted

Nov 19, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by argenx on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.